Highlights Carna Biosciences, Inc.

Equities

4572

JP3220550002

Market Closed - Japan Exchange Other stock markets 07:00:00 17/05/2024 BST			5-day change	1st Jan Change
436 ^JPY	+0.23%		+1.40%	-16.48%

03-07	Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	CI
2023	Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	03-07	CI
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	09/05/22	CI
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	02/02/22	MT
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	02/02/22	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	05/08/21	CI
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	05/08/21	CI
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12/02/21	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	12/02/21	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	08/11/20	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	08/11/20	CI
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	12/05/20	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	12/05/20	CI
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	07/02/20	CI
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019	09/01/20	CI
Open Orphan Signs Contract with Carna Bioscience	18/11/19	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	07/11/19	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	12/08/19	CI
Gilead Sciences, Inc. and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies	24/06/19	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	13/05/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Carna Biosciences, Inc.

Equities

4572

JP3220550002

Highlights

Filters